Versant Venture Management, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 5, 2026), Versant Venture Management, LLC reported 8 stock positions worth $141.4 million. Its top holding was Monte Rosa Therapeutics (GLUE) at 37.0% of the portfolio, followed by Century Therapeutics (IPSC, 19.4%) and Lenz Therapeutics (LENZ, 17.2%). Compared with Q4 2025, it opened 1 new position and reduced 1. The biggest buy was a new position in Century Therapeutics (IPSC) and the biggest sale Monte Rosa Therapeutics (GLUE, shares −27%).

Most Recent 13F
Q2 2026
Location
San Francisco, CA
CIK
0001560009
Portfolio Value
$141.4M (Q1 2026)
SEC Filing
0001193125-26-206555 ↗ filed May 5, 2026

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q1 2024: $103.1M Q1 2024 Q2 2024: $77.3M Q2 2024 Q3 2024: $63.6M Q3 2024 Q4 2024: $86.7M Q4 2024 Q1 2025: $60.2M Q1 2025 Q2 2025: $82.1M Q2 2025 Q3 2025: $212.5M Q3 2025 Q4 2025: $151.1M Q4 2025 Q1 2026: $141.4M $141.4M Q1 2026 Q2 2026: $162.6M Q2 2026

Holdings 8 stocks · $141.4M
GLUE Monte Rosa Therapeutics Inc. 37.00% 3,180,780 $52.3M Reduce -27.4%
IPSC Century Therapeutics Inc. 19.44% 12,166,109 $27.5M New
LENZ Lenz Therapeutics Inc. 17.19% 2,656,888 $24.3M No change
JBIO Jade Biosciences Inc. 15.16% 1,525,820 $21.4M No change
CTNM Contineum Therapeutics Inc. Class A 5.01% 542,628 $7.1M No change
CRSP Crispr Therapeutics AG 5.01% 148,831 $7.1M No change
SKYE Skye Bioscience Inc. 0.87% 2,007,704 $1.2M No change
TPST Tempest Therapeutics Inc. 0.31% 269,772 $442K No change

Portfolio Sells Q4 2025 → Q1 2026
GLUE Monte Rosa Therapeutics Inc. Reduce -27.4% 37.00% −8.49

Portfolio Buys Q4 2025 → Q1 2026
IPSC Century Therapeutics Inc. New 19.44% +19.44

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 8$162.6MGLUE, IPSC, JBIO, LENZ, CTNM
Q1 2026 8$141.4MGLUE, IPSC, LENZ, JBIO, CTNM
Q4 2025 7$151.1MGLUE, LENZ, JBIO, CRSP, CTNM
Q3 2025 9$212.5MLENZ, GLUE, JBIO, CRSP, SKYE
Q2 2025 8$82.1MGLUE, CRSP, JBIO, SKYE, RPTX
Q1 2025 7$60.2MGLUE, CRSP, CTNM, SKYE, RPTX
Q4 2024 7$86.7MGLUE, CRSP, CTNM, SKYE, RPTX
Q3 2024 6$63.6MCRSP, CTNM, RPTX, SKYE, ADVM
Q2 2024 8$77.3MCRSP, CTNM, SKYE, RPTX, ADVM
Q1 2024 7$103.1MCRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM